Several preclinical and translational studies suggest that adding to ICIs a second agent, such as chemotherapy, CDK4/6i, or PARPi, may elicit an anti-tumor immune response, ultimately resulting in a synergistic effect [10,39,40]. Here, CDK4 is linked to neoplasm.